BioSpace News Archive

Med-X, Inc. -- On May 26, 2020 Med-X, Inc. announced the launch of a Regulation Crowdfunding campaign on the Crowdfunding portal TruCrowd.

NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President Shigenobu Maekawa), announced today that JAMA Neurology has published results from a clinical trial of viltolarsen, an investigational agent being evaluated in Duchenne muscular dystrophy (DMD) patients who are amenable to exon 53 skipping therapy.

Oncopeptides AB ‘s Annual General Meeting 2020 was held , at Tändstickspalatset in Stockholm.

Tauriga Sciences Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with proprietary CBD & CBG infused chewing gums and edibles product(s) as well as two ongoing Biotechnology initiatives, today announced the arrival of Peach-Lemon flavor Cannabigerol (“CBG”) infused Tauri-Gum™ inventory – at its E-Commerce fulfillment center.

Los Angeles Surgeon Gabriel Goren, MD says ‘Rejuvahands TM’ is the ONLY enduring option for seniority associated unsightly looking bulging hand vein

Shuwen Biotech Co. Ltd., a China-based leader in innovative diagnostics announced today the peer-reviewed publication of data highlighting the potential of its breakthrough point-of-care test in rapidly diagnosing Preeclampsia among women who are admitted to the hospital. The paper, entitled “Late pregnancy screening for preeclampsia with a urinary point-of-care test for misfolded proteins”, w

Abivax SA (Euronext Paris: FR0012333284 – ABVX), a late stage clinical biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, announces today that the German regulatory authority for drugs and medical products, BfArM (Bundesinstitut für Arnzeimittel und Medizinprodukte), has approved its Phase 2b/3 study of ABX464 in COVID-19 patients.

Aclaris Therapeutics, Inc., a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, announced that management will present a company overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 1:00 p.m. ET.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management will review initial results from the ALLO-501 ALPHA Phase 1 trial in relapsed/refractory non-Hodgkin lymphoma on May 29, 2020 via a live webinar at 5:30 AM Pacific Time/8:30 AM Eastern Time.

ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that the Company will release its first quarter 2020 financial results on Thursday, May 28, 2020, before the U.S. financial markets open. Larry